SEC Form 4 · accession 0001012975-15-000230
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Other
Period of report
Mar 13, 2015
Accepted (ET)
Mar 17, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F3 | Mar 13, 2015 | J | 475,000 | $0.00 | D | 947,309 | I | By ARCH Venture Fund VI, L.P. |
| Common Stock | Mar 13, 2015 | J | 1,766 | $0.00 | A | 4,308 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person ceased to be a director of the Issuer on December 31, 2014 but remains subject to certain reporting obligations under Rule 16a-2(b) promulgated under the U.S. Securities and Exchange Act of 1934.
- F2Distribution of Common Stock held by a limited partnership to its partners for no consideration.
- F3These shares are owned directly by ARCH Venture Fund VI, L.P., or ARCH Fund VI. The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P., or ARCH Partners VI. The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC, or ARCH VI LLC. The Managing Directors of ARCH VI LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VI. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.
- F4Change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person.